San Francisco, CA - 89bio, Inc., a clinical-stage biopharmaceutical company with a laser focus on delivering cutting-edge therapies for liver and cardio-metabolic diseases, is making waves. The company's lead product candidate, pegozafermin, is the object of much excitement in the industry due to its remarkable potential for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. Pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 that has caught the attention of many observers in the field due to its breathtaking clinical results. Founded in 2018, 89bio, Inc. has quickly established itself as a leader in the field of biopharmaceuticals. Headquartered in San Francisco, the company is leveraging cutting-edge research and development to drive the next generation of anti-liver and cardio-metabolic disease treatments. With a keen eye on the market, 89bio, Inc. is a company to watch closely as it continues to make strides in the field of biopharmaceuticals.